Silence Therapeutics to present divesiran Phase 2 data at ASH 2026
Tweet Send to a Friend
Silence Therapeutics plc (Nasdaq: SLN) announced that data from its SANRECO Phase 2 study of divesiran in polycythemia vera will ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




